Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience

Four prospective trials have reported apatinib-related efficacy in osteosarcoma, with a high response rate of 43.2%. Currently, Adverse Events (AEs) have increasingly gained attention, as treatment with multiple tyrosine kinase inhibitors (TKIs) is potentially lifelong. For this reason, a consensus...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Lu, Xu, Jie, Guo, Wei, Wang, Zhen, Yao, Yang, Li, Jianmin, Lin, Jianhua, Xiao, Jianru, Yu, Xiuchun, Zhang, Weibin, Cai, Zhendong, Hua, Yingqi, Chen, Jing, Shao, Zengwu, Wu, Di, Wu, Sujia, Tu, Zhongqi, Zhang, Xiaojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339966/
https://www.ncbi.nlm.nih.gov/pubmed/34367981
http://dx.doi.org/10.3389/fonc.2021.696865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339966/
https://www.ncbi.nlm.nih.gov/pubmed/34367981
http://dx.doi.org/10.3389/fonc.2021.696865

Ejemplares similares